Correcting Genetic Spelling Errors With Next-Generation Crispr
Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...
Check Out What Whales Are Doing With CRSP
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...
Pharmabiz1h
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease: Hyogo, Japan Tuesday, January 7, 20 ...
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to “Sell” Rating
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...
Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...